期刊文献+

升结肠支架置入腹膜炎脓毒症模型的应用研究 被引量:4

Application research of a novel sepsis model design by colon ascendens stent peritonitis
暂未订购
导出
摘要 目的探讨建立研究脓毒症发病机制的动物模型。方法采用3种型号管径的静脉留置BD套管针做为支架构建脓毒症的动物模型,通过术后一般表现、不同管径支架的CASP模型的生存时间及生存率、各器官HE染色行组织病理学的检测、腹腔分泌物微生物实验室检查比较升结肠支架置入腹膜炎脓毒症模型的严重程度及稳定性。结果CASP模型各组的生存时间取决于置入支架的直径,支架直径越大死亡率越高,24h解剖发现腹腔呈明显腹膜炎表现;组织病理切片结果显示小肠黏膜明显坏死脱落、绒毛萎缩,心、肺、肾、脾脏有炎性细胞浸润等炎症表现;腹腔内分泌物培养检测到肠道细菌如革兰阴性大肠埃希氏菌、杆菌种、肠球菌。结论升结肠支架置入腹膜炎模型,操作简单,具有可重复性,可以模仿人类弥漫性腹膜炎疾病过程,适用于外科脓毒症的研究。 Objective To explore the establishment of an animal model for the pathogenesis of sepsis.Methods Use three models with diameter of venous indwelling trocar BD as a scaffold to build animal models of sepsis,to compare ascending colon stenting peritonitis the severity of the sepsis model and stability by postoperative general performance,different diameter stents CASP model of survival time and survival rate,each organ HE dyeing line histopathological examination,abdominal fluid microbiology laboratory examination.Results The survival time of the CASP model group depends on the diameter of the placement of stents,the longer the stent diameter the bigger the mortality rate.24h autopsy found abdominal cavity peritonitis remarkable performance,Histopathologic biopsy results show that the small intestinal mucosa obvious necrosis falls off,fluffy atrophy,heart,lung,kidney,spleen with inflammatory cells infiltration and inflammation performance;Intra-abdominal intestinal secretion culture detected such as gram-negative bacteriae.coli,bacillus species,enterococcus.Conclusion The ascending colon stent peritonitis model,which is more simple and reproducible,can imitate human surgery operation treatment of infection,and applied to the research of the surgical sepsis.
出处 《江西医药》 CAS 2013年第3期203-204,212,共3页 Jiangxi Medical Journal
基金 江西省科技厅青年科学基金资助项目(20112BAB205033) 江西省卫生厅科技计划项目(20121023)
关键词 脓毒症 腹膜炎 模型 小鼠 Sepsis Peritonitis Model Mouse
  • 相关文献

参考文献7

  • 1Martin G S,Mannino D M,Eaton S,et al.The epidemiology of sepsis in the United States from 1979 through 2000New England Journal of Homeopathy,2003.
  • 2王联群.免疫营养对外科脓毒症的治疗研究[J].江西医药,2008,43(10):1005-1006. 被引量:3
  • 3Robinson K,Kruger P,Prins J,et al.The metabolic syndrome incritically ill patientsBailliere s Best Practice and Research Clinical Endocrinology and Metabolism,2011.
  • 4Angus DC,Linde-Zwirble WT,Lidicker J,et al.Epidemiology of severe sepsis in the United States: analysis of incidence,outcome, and associated costs of careCritical Care Medicine,2001.
  • 5Dombrovskiy VY,Martin AA,Sunderram J,et al.Rapid increase inhospitalization and mortality rates for severe sepsis in the UnitedStates:Atrend analysisfrom1993 to 2003Critical Care Medicine,2007.
  • 6陈海鸣,李学明.脓毒症动物实验模型研究进展[J].江西医药,2012,47(10):937-939. 被引量:9
  • 7陈海鸣.高容量血液滤过对外科脓毒症的治疗研究[J].江西医药,2009,44(1):1-3. 被引量:2

二级参考文献20

  • 1Sung-LingYeh,Yu-NiLai,Huey-FangShang,Ming-TsanLin1,Wan-ChunChiu,Wei-JaoChen.Effects of glutamine supplementation on splenocyte cytokine mRNA expression in rats with septic peritonitis[J].World Journal of Gastroenterology,2005,11(12):1742-1746. 被引量:14
  • 2Bone R C,Balk R A,Cerra F B,et al.Definitions for sepsis and organ failure and guide lines for the use of innovative therapiesin sepsis.The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians Society of Critical Care Medicine.Chest, 1992,101 : 1644
  • 3Canepari G,Inquaqqiato P,Giqliola G,et al.Continuousrenal replacement therapies (CRRT).G Ital Nefrol,2006,23 (36):30
  • 4Dellinger RP,Lew MM,Carlet JM,et al.Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock : 2008.Intensive Care Med, 2008,34(1) : 17
  • 5Bouman CS,Oudemans-van Straaten HM,Schultz MJ,et al.Hemofiltration in sepsis and systemic inflammatory response syndrome:The role of dosing and timing.Crit Care, 2007,22(1) : 1
  • 6Piccinni P, Dan M, Barbacini S,et al.Early isovolaemic haemofiltration in oliguric patients with septic shock.Intensive Care Med, 2006, 32(1) : 80
  • 7Comejo R, Downey P, Castro R,et al.High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock.lntensive Care Med, 2006,32(5) : 713
  • 8Angus DC,Linde-Zwirble WT, Lidicker J,et al. Epidemiology of se-vere sepsis in the United States: analysis of incidence, outcome,and associated costs of care.Crit Care Med, 2001,29(7):1303.
  • 9HubbardWJ. Choudhry M,Schwacha MG, et al. Cecal ligation andpuncture. Shock, 2005, 24 (Suppl 1): 52.
  • 10ParkerSJ,Watkins PE. Experimental models of gram -negativesepsis. Br J Surg, 2001,88(1):22.

共引文献13

同被引文献21

引证文献4

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部